Liquid biopsy-based biomarker for endometrial cancer diagnosis and use thereof
Patent Information
- Application Number
- KR1020220118114
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-09-19
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-09-19
Smart Images

Figure 112022098364097-PAT00004_ABST
Abstract
Claims
Claim 1 A biomarker composition for predicting or diagnosing endometrial cancer, characterized in that the composition is detected in ctDNA extracted from plasma and / or peritoneal fluid, comprising a POLE, and is endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the POLE gene: (a) a frameshift mutation p.V1446fs; and (b) a missense mutation p.R2165H. Claim 2 The biomarker composition of claim 1, wherein the biomarker composition further comprises TP53 and is endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the TP53: (a) a frameshift mutation which is p.P20fs, p.S37fs, p.C3fs, or p.K250fs; (b) a nonsense mutation which is p.R174X; and (c) a missense mutation which is p.R248Q or p.R181C. Claim 3 A biomarker composition according to claim 1, wherein the biomarker composition further comprises PTEN, and is characterized by being endometrial cancer positive when a missense mutation p.R130Q and / or p.Y27N is detected in the PTEN. Claim 4 A biomarker composition according to claim 1, wherein the biomarker composition further comprises KRAS, and is endometrial cancer positive when a missense mutation, p.G13D and / or p.G12A, is detected in the KRAS. Claim 5 A biomarker composition according to claim 1, wherein the biomarker composition further comprises PIK3CA, and is endometrial cancer positive when one or more missense mutations selected from the group consisting of p.R38H, p.Q546P, p.H1047Y, and p.R38C are detected in the PIK3CA. Claim 6 delete Claim 7 The biomarker composition of claim 1, wherein the biomarker composition further comprises ARID1A and is endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in ARID1A: (a) an in-frame mutation p.1326_1327del; (b) a frameshift mutation p.S2179fs, p.M793fs, p.D2260fs, p.P1467fs, p.P1897fs, p.V132fs, p.P2139fs, p.A1517fs, p.G1848fs, p.P549fs, p.Y1324fs, or p.Y222fs; (c) p.R2158X, p.Y1012X, p.R1276X, or (d) a nonsense mutation p.Q537X; and (d) a missense mutation M1388V or p.T1649I. Claim 8 A biomarker composition according to claim 1, wherein the biomarker composition further comprises CTNNB1, and is characterized by being endometrial cancer positive when one or more missense mutations selected from the group consisting of p.D32Y, p.R486C, p.D32N, p.H737Q, and p.I35S are detected in CTNNB1. Claim 9 The biomarker composition of claim 1, wherein the biomarker composition further comprises KMT2C and is characterized as being endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the KMT2C: (a) a frameshift mutation p.K2797fs; (b) a nonsense mutation p.Q755X; and (c) missense mutations that are p.A3366T, p.R380L, p.G315S, p.R284Q, p.S764F, p.D348N, p.K339N, p.S338L, p.E765G, p.G315C, p.G865D, p.E387Q, p.L4264M, p.Q2632P, p.S349N, p.A3222V, p.T820I, or p.K3620N. Claim 10 A biomarker composition according to claim 1, wherein the biomarker composition further comprises PRKAR1A, and is characterized by being endometrial cancer positive when a nonsense mutation p.X338E is detected in PRKAR1A. Claim 11 A biomarker composition according to claim 1, wherein the biomarker composition further comprises NOTCH2, and is characterized by being endometrial cancer positive when one or more missense mutations selected from the group consisting of p.N2265K, p.H107P, p.I2310L, and p.H1390L are detected in the NOTCH2. Claim 12 The biomarker composition of claim 1, wherein the biomarker composition further comprises USP6 and is endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the USP6: (a) an in-frame mutation, c.201_202GT; (b) a frameshift mutation, p.R1249fs; and (c) a missense mutation, p.M80I, p.K66Q, p.R69W, p.L121S, p.G125R, p.R126K, p.Q128K, or p.S1148L. Claim 13 The biomarker composition of claim 1, wherein the biomarker composition further comprises SDHA and is endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the SDHA: (a) a frameshift mutation p.T567fs; and (b) a missense mutation p.A69T, A466T, p.R465Q, p.V446A, p.A449V, p.S456L, p.C467S, or p.A454T. Claim 14 The biomarker composition of claim 1, wherein the biomarker composition further comprises POLQ, and is characterized as being endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the POLQ: (a) a frameshift mutation p.L1430fs; and (b) a missense mutation p.R137W or p.R2347H. Claim 15 A biomarker composition according to claim 1, wherein the biomarker composition further comprises PREX2, and is characterized by being endometrial cancer positive when a missense mutation p.N473K is detected in the PREX2. Claim 16 A biomarker composition according to claim 1, wherein the biomarker composition further comprises CASP8, and is characterized by being endometrial cancer positive when a nonsense mutation p.Y319X and / or a missense mutation p.A326V is detected in CASP8. Claim 17 The biomarker composition of claim 1, wherein the biomarker composition further comprises SF3B1 and is endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in SF3B1: (a) a frameshift mutation p.M378fs; (b) an in-frame mutation p.S377delinsTPC; and (c) a missense mutation p.Q29P, p.G742D, or p.R387W. Claim 18 The biomarker composition of claim 1, wherein the biomarker composition further comprises MYCN and is characterized as being endometrial cancer positive when one or more mutations selected from the group configured as follows are detected in the MYCN: (a) a frameshift mutation p.H29fs; (b) an in-frame mutation p.H29delinsHPPPP; and (c) a missense mutation p.R31P, p.G159D, p.G34R, or p.G37R. Claim 19 A biomarker composition according to claim 1, wherein the biomarker composition further comprises MYC, and is characterized by being endometrial cancer positive when an in-frame mutation, p.70_74del and / or p.41_41del, is detected in the MYC. Claim 20 A biomarker composition according to claim 1, wherein the biomarker composition further comprises one or more selected from the group consisting of POLQ, PREX2 and SOX17, and is characterized as being endometrial cancer positive when copy number gain is detected in POLQ, PREX2 or SOX17. Claim 21 A biomarker composition according to claim 1, wherein the biomarker composition further comprises one or more selected from the group consisting of MYCN, SF3B1, and CASP8, and is characterized as being endometrial cancer positive when copy number loss is detected in MYCN, SF3B1, or CASP8. Claim 22 A composition for predicting or diagnosing endometrial cancer comprising a substance capable of detecting a biomarker composition of any one of claims 1 to 5 and claims 7 to 21. Claim 23 A composition according to claim 22, characterized in that the substance capable of detecting the biomarker composition is a probe or a primer. Claim 24 A kit for diagnosing endometrial cancer comprising the composition of claim 22. Claim 25 A method for providing information for the prediction or diagnosis of endometrial cancer comprising the following steps: (a) extracting gDNA from tissue isolated from a biological sample of a subject to diagnosis, ctDNA from peritoneal fluid and / or ctDNA from plasma; (b) detecting mutations in the POLE gene in the extracted gDNA and / or ctDNA; and (c) classifying the likelihood of developing endometrial cancer as high when mutations in the gene are detected: wherein, in step (b), the mutations in the POLE gene are (i) a frameshift mutation, p.V1446fs; or (ii) a missense mutation, p.R2165H. Claim 26 A method according to claim 25, characterized in that the biological sample is one or more selected from the group consisting of tumor tissue, blood, and peritoneal cell fluid.
